Skip to main content
Back
Watch Compare

Mereo BioPharma Group plc

Data quality: 100%
MREO
NASDAQ Manufacturing Chemicals
$0.33
▲ $0.01 (2.19%)
6 months return
—
Momentum
Neutral
ROE
-83.11%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-83.11%
Below sector avg (-54.49%)
ROIC-61.73%
Net Margin-8375.60%
Op. Margin-8021.40%

Safety

Debt / Equity
N/A
Current Ratio8.71
Interest Coverage-157.28

Valuation

PE (TTM|NTM)
-1.21 | -11.06
Above sector avg (-1.50)
P/B Ratio1.09
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -30.99 M
Capital efficient — spends only 4.00% of revenue on capex

Price History

Financial Trends

Analyst Price Target

6 analysts
Buy
+437.5%
upside to target
Current
$0.33
Consensus Target
$1.76
$0.50
Low
$3.01
High
Forecast
Forward P/E
-11.06
Forward EPS
-$0.03
Est. Revenue
17.14 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: $0.00 · Rev Est: 4.36 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.02 -$0.01 -$0.01 -$0.01 — —
Estimate -$0.01 -$0.01 $0.00 -$0.01 $0.00 -$0.01
Surprise -37.64% -65.78% -117.14% -7.14% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) -77.64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -83.11% · Net Margin: -8375.60%
Revenue (TTM) 500,000.0 Net Income (TTM) -41.88 M
ROE -83.11% ROA -72.06%
Gross Margin N/A Operating Margin -8021.40%
Net Margin -8375.60% Free Cash Flow (TTM) -30.99 M
ROIC -61.73% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 8.71
Debt / Equity N/A Current Ratio 8.71
Interest Coverage -157.28 Asset Turnover 0.01
Working Capital 46.39 M Tangible Book Value 45.96 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.21 · EV/EBITDA: N/A
P/E Ratio -1.21 Forward P/E -11.06
P/B Ratio 1.09 P/S Ratio 101.48
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2.96 Fwd Earnings Yield N/A
FCF Yield -61.08%
Market Cap 50.74 M Enterprise Value 2.04 M

Per Share

EPS: -0.05 · FCF/Share: -0.19
EPS (Diluted TTM) -0.05 Revenue / Share 0.00
FCF / Share -0.19 OCF / Share -0.19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 74.00% · CapEx/Rev: 4.00%
CapEx / Revenue 4.00% FCF Conversion 74.00%
SBC-Adj. FCF -39.10 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 500,000.0 0.0 10.00 M
Net Income -41.88 M -43.25 M -29.47 M
EPS (Diluted) -0.05 -0.06 -0.04
Gross Profit — — —
Operating Income -40.11 M -47.36 M -28.42 M
EBITDA — — —
R&D Expenses 17.77 M 20.93 M 17.42 M
SG&A Expenses — — —
D&A — — —
Interest Expense 255,000.0 1.37 M 2.88 M
Income Tax 0.0 0.0 -532,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 45.92 M 76.39 M 66.50 M
Total Liabilities 5.00 M 15.42 M 15.96 M
Shareholders' Equity 40.92 M 60.97 M 50.54 M
Total Debt — — —
Cash & Equivalents 40.99 M 69.80 M 57.42 M
Current Assets 45.02 M 74.76 M 63.76 M
Current Liabilities 4.30 M 13.85 M 9.49 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -1.2 -1.5
P/B 1.1 1.6
ROE % -83.1 -54.5
Net Margin % -8375.6 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock
BBC logo BBC Virtus Biotech Clinical Trials ETF
0.49% weight
CANC logo CANC Tema Oncology ETF
0.47% weight